Home / Business and Economy / Sudarshan Pharma Soars on NSE Main Board Listing
Sudarshan Pharma Soars on NSE Main Board Listing
28 Oct
Summary
- Sudarshan Pharma shares climbed 7% following its NSE main board listing.
- The company's board will review Q2 FY27 results and fundraising on October 29.
- The stock has shown significant returns, nearly 60% in the past year.
Sudarshan Pharma Industries Limited shares experienced a notable 7% increase on Wednesday, marking its formal listing on the main board of the National Stock Exchange (NSE). This significant corporate action involved the company's migration from the BSE's SME platform to the NSE's Capital Market Segment, effective Tuesday, October 27, 2026.
Further boosting investor interest, the Maharashtra-headquartered pharmaceutical firm's board of directors is scheduled to convene on Thursday, October 29, 2026. During this meeting, they will review the financial results for the second quarter of the fiscal year 2026-27. Additionally, the board will deliberate on a potential fundraising proposal.
The fundraising initiative may involve the issuance of various instruments, including equity shares, convertible securities, warrants, or debt securities. This could be executed through private placement, preferential issue, Qualified Institutions Placement, or other combined methods. The stock has demonstrated robust performance, with a one-year return of approximately 61.77%.
